Kura Oncology (KURA) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis initiated coverage with a Buy rating on Kura Oncology (KURAResearch Report) today and set a price target of $32.00. The company’s shares closed last Friday at $16.25.

According to, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.2% and a 27.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $33.33, which is a 101.1% upside from current levels. In a report issued on April 9, Brookline Capital Markets also maintained a Buy rating on the stock with a $56.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $30.37 and a one-year low of $11.49. Currently, Kura Oncology has an average volume of 865.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Read More on KURA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More